{"schema_version":"secwatch.filing_event.v1","accession":"0001867096-26-000004","form_type":"8-K","ticker":"XERS","cik":"0001867096","company_name":"Xeris Biopharma Holdings, Inc.","filed_at":"2026-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.613021+00:00","generated_at":"2026-05-16T11:15:26.310516+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Xeris expects record 2025 revenue of $292M, up 44% YoY; beats guidance","bullets":["Preliminary full-year 2025 total revenue of $292M, exceeding $285-290M guidance range, reflecting 44% YoY growth.","Q4 Recorlev net revenue $45M; full-year Recorlev net revenue $139M.","Gvoke revenue grew >13% YoY; Keveyis patient base expanded vs. year-end 2024.","Positive Adjusted EBITDA delivered in each quarter of 2025.","Full 2025 results and 2026 outlook to be released March 2, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001867096-26-000004","json":"https://secwatch.observer/filing/0001867096-26-000004.json","markdown":"https://secwatch.observer/filing/0001867096-26-000004.md","text":"https://secwatch.observer/filing/0001867096-26-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1867096/000186709626000004/0001867096-26-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1867096/000186709626000004/xers-20260108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:15:26.310516+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}